By proceeding, you agree to our Terms of Use and Privacy Policy.
Turbocharge the Development of Best-In-Class Treg-Directed Therapies, Maximizing Stability and Function to Deliver Safe, Scalable and Efficacious Therapies Globally As Biopharma turn their focus to autoimmune drug development, there has been an explosion of interest and investment into Treg directed therapies.
Speaker presentations will focus on optimizing the stable expansion of Tregs to maintain function, to elicit durable responses.
Discussions will revolve around rationalizing activation, formulation & delivery strategy to induce antigen-specific tolerance.
Learn how to decode Treg interactions in order to create durable responses and yield maximum clinical efficacy.
Hanson Wade gives people the clarity to see where opportunity lies. We work in highly specialised fields to provide unmatched depth and quality of content. We work in sectors where quality of information is the difference between success and failure.
Adaptive Biotechnologies is a pioneer and leader in immune-driven medicine that aims to improve people’s lives by learning from the wisdom of their adaptive immune systems.
At Harvard Medical School, our mission is to create and nurture a diverse community of the best people committed to leadership in alleviating human suffering caused by disease.
Revolo Biotherapeutics is developing revolutionary therapies powered to reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases.
Key technical assets of TeraImmune 1) Expansion of human regulatory T cells in vitro 2) Receptors targeting pathological immune cells (T cell/ B cell/ antigen presenting cell)
All trademarks, registered trademarks, product names, and company names or logos mentioned in or on this site are the property of their respective owners.
A great community. Legit content. The kind of emails you actually look forward to.